The 16-week, double-blind, placebo-controlled, multicenter, parallel-group study included 698 patients who were randomized to 3 treatment groups: 2 doses of tanezumab 2.5mg; 1 dose of tanezumab 2.5mg followed by tanezumab 5mg, or 2 doses of placebo; each injection was administered once every 8 weeks.
Patient-centered recommendations released by the European League Against Rheumatism
Consensi combines amlodipine besylate, a calcium-channel blocker (CCB), and celecoxib, a nonsteroidal anti-inflammatory drug (NSAID).
In patients with rheumatoid arthritis or osteoarthritis who are at higher risk for cardiovascular events, celecoxib may be safer compared with naproxen or ibuprofen when these drugs are taken alone or in combination with aspirin.
EULAR has released recommendations to enable health professionals to provide knowledgeable pain management support for patients with inflammatory arthritis and osteoarthritis.
Patients who received a repeat Zilretta injection experienced a 64% improvement in Western Ontario and McMaster Universities Arthritis Index (WOMAC)-A (pain), a 66% improvement in WOMAC-B (stiffness), a 64% improvement on WOMAC-C (function), and improvement represented by a doubling of the KOOS Quality of Life subscale score by Week 4.
The randomized, double-blind, controlled trial (N=24,081) included patients with rheumatoid arthritis or osteoarthritis who required chronic NSAID treatment.
In patients with painful hip osteoarthritis, an intramuscular glucocorticoid injection may effectively alleviate hip pain in the short-term.
Fibromyalgia, osteoarthritis, sciatic syndrome, rheumatoid arthritis, and moderate depression may be more prevalent in working-age individuals with vs without migraine.
Laparoscopic gastric band surgery is associated with more improvement in knee osteoarthritis in younger patients and those without prior knee injury.
Intravenous and subcutaneous administration of tanezumab may provide similar analgesia and tolerability in patients with hip or knee osteoarthritis.
In clinical trials, treatment with Durolane resulted in greater reduction in Visual Analog Scale (VAS) pain scores at 3 and 6 months compared to Synvisc One (hylan G-F 20; Sanofi Genzyme).
The available evidence suggests that radiofrequency ablation is a feasible treatment option for chronic hip pain associated with degenerative diseases.
Opioids and nonopioid analgesics were found to provide similar improvements in pain-related function over a 1-year period in patients with chronic back pain or knee or hip osteoarthritis pain.
The effects of glucosamine supplements in the treatment of patients with painful temporomandibular joint osteoarthritis were not superior to the effects of ibuprofen taken 2 to 3 times per day.
Hydroxychloroquine was no more effective than placebo in reducing symptoms or radiographic progression in patients with moderate to severe hand pain and radiographic osteoarthritis.
Pain relief of at least 50% following a prognostic genicular nerve block may not predict pain relief following genicular nerve cooled radiofrequency ablation in patients with chronic knee pain due to osteoarthritis.
Unilateral and bilateral knee pain may be associated with development of prefrailty and frailty over 6 years.
Rainfall may not be associated with joint or back pain in older Medicare beneficiaries.
Patients with osteoarthritis who achieved a >10% weight loss were found to have reduced cartilage degeneration, compared with patients achieving only moderate or no weight loss.
In addition to being safer and more cost-effective, short-acting opioids are comparable with long-acting opioids for pain management in patients with chronic osteoarthritis.
Gloves with small vibrating motors may safely reduce hand pain among women with osteoarthritis during and after use.
The FDA has approved Durolane for the treatment of pain associated with knee osteoarthritis, which relieved pain and restored function for up to 6 months in patients.
Extended-release paracetamol may have a greater analgesic effect than placebo in patients with osteoarthritic knee pain.
Researchers examined alcohol consumption, smoking status, and body mass index as variables impacting patients' risk of osteoarthritis development or progression.
Patients with HIV who underwent immediate ART saw significant decreases in bone mineral density; however, the benefits of beginning ART early outweigh the outcomes related to decreased BMD.
Consuming more dairy product may raise the risk for total hip arthroplasty for osteoarthritis in men.
Diclofenac at 150 mg/day is the most effective NSAID for treating osteoarthritic pain and physical disability, while paracetamol had nearly no effect.
Approximately 37% of US adults aged 60 years and older have been diagnosed with knee osteoarthritis, and the number is expected to rise.
Positive psychosocial interventions improved symptom severity, quality of life, and mood in Veteran Administration patients with osteoarthritis of the hip and knee.
Clinical Pain Advisor Articles
- Opioid Use Disorders: Advances in Pharmacotherapy Provide Long-term Results
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- FDA Taps Social Media to Identify and Assess Emerging Drug Abuse Threats
- Buffered Lidocaine May Be Superior to Nonbuffered Lidocaine for Inferior Alveolar Nerve Block
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Marijuana's Uncertain Status: Closing the Gap Between State and Federal Policies